Targeting histone deacetylases for the therapy of Myc-induced malignancies

靶向组蛋白脱乙酰酶治疗 Myc 诱导的恶性肿瘤

• 批准号: nhmrc : 1006002
• 负责人: A/Pr Christopher Scarlett
• 金额: $ 23.77万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-histone-deacetylases-induced-malignancies/109133
• 关键词: Targeting; histone; deacetylases; therapy; Myc

Neuroblastoma is the commonest solid tumour in early childhood. Pancreatic cancer is the fourth leading cause of cancer death in adults. In this application, we will define how proteins called histone deacetylases promote cancer initiation and progression, and whether combination therapy with an inhibitor of the histone deacetylases and another anti-cancer agent exert efficient synergistic anti-cancer effects in animal models of neuroblastoma and pancreatic cancer.

神经母细胞瘤是儿童早期最常见的实体瘤。胰腺癌是成人癌症死亡的第四大原因。在本申请中，我们将定义称为组蛋白脱乙酰酶的蛋白质如何促进癌症的发生和进展，以及组蛋白脱乙酰酶抑制剂和另一种抗癌剂的联合治疗是否在神经母细胞瘤和胰腺癌的动物模型中发挥有效的协同抗癌作用。